GlassScriptPhysician profile
Jiun L DO
NPI 1578900205
$7,479.43
in general payments reported to CMS, 2019-2025
11 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what 85% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.76 · 2020: $18.19 · 2021: $518 · 2022: $1,826 · 2023: $965 · 2024: $1,644 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613 · Travel and Lodging: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.57 |
| Travel and Lodging | $1,448.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,822.15 | 2022-2025 | Xen Glaucoma Treatment System, Vuity, Lumigan |
| Bausch & Lomb Americas INC. | $1,812.25 | 2022-2025 | |
| New World Medical,INC. | $1,065.18 | 2023-2024 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Alcon Vision LLC | $809.14 | 2019-2025 | Hydrus Microstent, Centurion |
| Sight Sciences, INC. | $703.47 | 2021-2025 | Tearcare System, Omni Surgical System |
| Allergan, INC. | $537.61 | 2021-2022 | |
| Glaukos Corporation | $511.95 | 2022-2025 | Idosetr, Istent Infinite, Istent Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $101.76 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $84.78 | 2024-2025 | Tecnis Iol, Tecnis Simplicity |
| Aerie Pharmaceuticals, INC. | $20.93 | 2021 | |
| Iridex Corporation | $10.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiun DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.